-logo-1200x675.png?v=20220303080937){kind=logo}
Oncology Institute (NASDAQ:TOI – Get Free Report) had its price objective raised by research analysts at BTIG Research from $8.00 to $9.00 in a research note issued on Thursday, MarketBeat.com reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 52.80% from the company’s current price.
TOI has been the subject of a number of other research reports. B. Riley Financial increased their price target on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Lake Street Capital started coverage on Oncology Institute in a report on Monday, July 6th. They set a “buy” rating and a $10.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Finally, Needham & Company LLC increased their price objective on shares of Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oncology Institute has an average rating of “Moderate Buy” and an average price target of $8.40.
Check Out Our Latest Stock Analysis on Oncology Institute
Oncology Institute Stock Performance
Oncology Institute (NASDAQ:TOI – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. The business had revenue of $147.44 million during the quarter, compared to analyst estimates of $142.10 million. As a group, equities analysts predict that Oncology Institute will post -0.17 earnings per share for the current year.
Insiders Place Their Bets
In related news, insider Yale Podnos sold 23,451 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the sale, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. This represents a 8.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mohit Kaushal sold 38,433 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $3.50, for a total value of $134,515.50. Following the completion of the sale, the director directly owned 172,583 shares in the company, valued at $604,040.50. This trade represents a 18.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders purchased 98,500 shares of company stock valued at $426,655 and sold 119,170 shares valued at $461,183. Company insiders own 4.40% of the company’s stock.
Hedge Funds Weigh In On Oncology Institute
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC increased its position in shares of Oncology Institute by 1.5% in the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock valued at $964,000 after acquiring an additional 3,900 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Oncology Institute by 9.1% during the 4th quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock worth $171,000 after acquiring an additional 4,007 shares during the last quarter. HighTower Advisors LLC raised its stake in Oncology Institute by 5.5% in the 4th quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock valued at $306,000 after acquiring an additional 4,489 shares during the period. Cetera Investment Advisers boosted its position in Oncology Institute by 35.0% during the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares during the period. Finally, R Squared Ltd boosted its holdings in shares of Oncology Institute by 42.7% during the 1st quarter. R Squared Ltd now owns 16,353 shares of the company’s stock worth $50,000 after buying an additional 4,891 shares during the period. 36.86% of the stock is owned by institutional investors and hedge funds.
About Oncology Institute
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
Featured Articles
- Five stocks we like better than Oncology Institute
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
- MarketBeat Week in Review – 07/06 – 07/10
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
